Etifoxine clinical trials

Validation of the 18 kiloDalton Translocator Protein (TSPO) as a Novel Neuroimmunodulatory Target

This study looks at new ways to treat multiple sclerosis (MS) by targeting a protein called TSPO. We're testing two drugs, XBD173 and Etifoxine, to see if they can reduce harmful immune activity in people with secondary progressive MS and in healthy volunteers.